<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998633</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN1204</org_study_id>
    <secondary_id>2U10HL069294-11</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT01998633</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)</brief_title>
  <acronym>RICHI</acronym>
  <official_title>Reduced-Intensity Conditioning for Children and Adults With Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI) (BMT CTN #1204)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HLH, HLH-related disorders, Chronic Granulomatous (CGD), HIGM1, Immune dysregulation,
      polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX) and severe LAD-I represent
      primary immune disorders that are typically fatal without Hematopoietic Cell Transplant
      (HCT). However, transplant is often complicated by inflammation, infection and other
      co-morbidities. In addition, these disorders have been shown to be cured with partial
      chimerism, making them an ideal target for the use of reduced intensity approaches, where a
      portion of patients may not achieve full donor chimerism, but instead achieve stable mixed
      chimerism. Reduced-intensity conditioning strategies have demonstrated improved survival with
      decreased Treatment Related Mortality (TRM) in institutional series for patients with HLH
      (Cooper et al., 2006; Marsh et al., 2010; Marsh et al., 2011). However, graft loss and
      unstable chimerism remain challenges. An institutional case series from Cincinnati Children's
      Hospital demonstrated full or high-level chimerism and improved durable engraftment using
      intermediate (Day -14) timing alemtuzumab (Marsh et al., 2013b). This study aims to test the
      efficacy of the Intermediate RIC strategy in a prospective multi-center study including HLH
      as well as other primary immunodeficiencies where allogeneic transplant with RIC has been
      shown to be feasible and stable chimerism is curative.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this Phase II clinical trial is to determine the one-year overall
      survival of patients treated for immune deficiencies including HLH, HLH-like disorders, CGD,
      HIGM1, IPEX syndrome, and severe LAD-I with Matched Related Donor (MRD)/ Matched Unrelated
      Donor (MUD) bone marrow transplant using a reduced-intensity conditioning strategy including
      intermediate-timing of alemtuzumab. The donor choice is an unaffected related bone marrow
      donor who is a 6/6 match at HLA-A, -B (intermediate or higher resolution) and -DRB1 (at high
      resolution using DNA-based typing) OR a 7/8 or 8/8 match for human leukocyte antigen (HLA)-A,
      -B, -C and -DRB1 (at high resolution using DNA-based typing), OR an unrelated bone marrow
      donor who is a 7/8 or 8/8 match at HLA-A, -B, -C and -DRB1 (at high resolution using
      DNA-based typing). The transplant conditioning regimen will include fludarabine, melphalan,
      and alemtuzumab starting at Day -14 (Flu/Mel/Alem). Graft Versus Host Disease (GVHD)
      prophylaxis will consist of cyclosporine and corticosteroids through engraftment.
      Post-transplant supportive care will include infection surveillance and prophylaxis, and
      disease-specific supportive care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">September 23, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS)</measure>
    <time_frame>1 year and 18 months post-transplant</time_frame>
    <description>Overall survival is defined as survival of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS) by Disease Type</measure>
    <time_frame>1 year and 18 months post-transplant</time_frame>
    <description>Overall survival is defined as survival of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HLH Participants With HLH Reactivation Post-Transplant</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Systemic HLH Reactivation: Post-transplant HLH reactivation is defined by clinical and lab evidence of pathologic inflammation (persistent fever, progressive cytopenias, rising ferritin and soluble IL2Rα, decreasing fibrinogen, hepatosplenomegaly, end-organ damage) not attributable to other causes.
Central nervous system (CNS) HLH Reactivation: Reactivation of CNS inflammation in patients with HLH may present with or without altered mental status and is defined by pleocytosis in Cerebrospinal fluid (CSF) or an MRI consistent with CNS inflammation not attributable to other causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Neutrophil Engraftment</measure>
    <time_frame>Day 42 post-transplant</time_frame>
    <description>Time to absolute neutrophil count (ANC) engraftment is defined as the first of three measurements on different days that the patient has an absolute neutrophil count of ≥ 500x10^6/liter following conditioning regimen induced nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Platelet Engraftment</measure>
    <time_frame>Day 100 post-transplant</time_frame>
    <description>Platelet engraftment is defined as the first day of a minimum of three measurements on different days that the patient has achieved a platelet count &gt; 20,000 / microliter AND the patient is platelet transfusion independent for a minimum of seven days following conditioning regimen induced nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive With Sustained Engraftment</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Sustained engraftment is defined as the occurrence of whole blood donor chimerism &gt; 5% by Day 42 accompanied by the absence of any primary or secondary graft failure. Primary graft failure is defined as &lt; 5% donor chimerism by Day +42, second stem cell infusion, DLI (except in the case of donor CTLs given for infection control), or second HCT following original HCT. Secondary graft failure is defined as &lt; 5% donor chimerism following initial engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive With Sustained Engraftment by Disease Type</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Sustained engraftment is defined as the occurrence of whole blood donor chimerism &gt; 5% by Day 42 accompanied by the absence of any primary or secondary graft failure. Primary graft failure is defined as &lt; 5% donor chimerism by Day +42, second stem cell infusion, DLI (except in the case of donor CTLs given for infection control), or second HCT following original HCT. Secondary graft failure is defined as &lt; 5% donor chimerism following initial engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade II-IV and Grade III-IV Acute GVHD</measure>
    <time_frame>Day 100 and 6 months post-transplant</time_frame>
    <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic GVHD</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Chronic GVHD</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <condition>Chronic Active Epstein-Barr Virus Infection</condition>
  <condition>Chronic Granulomatous Disease</condition>
  <condition>HIGM-1</condition>
  <condition>Leukocyte Adhesion Deficiency</condition>
  <condition>IPEX</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplant</intervention_name>
    <description>NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patient is ≥ 3 months and ≤ 45 years of age at time of enrollment.

          2. Meets criteria for one of the following immune disorders (2A-2F) requiring HCT:

        2A. HLH or related disorder with indication for HCT [a. Inherited gene mutation associated
        with HLH: PRF1, UNC13D (MUNC13-2), STXBP2 (MUNC18-2), STX11, RAB27A (Griscelli syndrome,
        type 2), SH2D1A (XLP1), XIAP (XLP2), LYST (Chediak-Higashi syndrome) - OR - b. Meets
        clinical criteria for HLH, refractory to therapy according to HLH-94 or HLH-2004
        (dexamethasone/etoposide), or recurrent episodes of hyper-inflammation - OR - c. Meets
        clinical criteria for HLH, without identified gene defects, with affected sibling - OR -
        decreased or absent NK cell function at the last evaluation, - OR - a history of CNS
        inflammation as evidenced by pleocytosis in CSF or MRI evidence of hyper-inflammation in
        the CNS]

        2B. CAEBV: Patients with chronic EBV infection (CAEBV) with or without associated lymphoma
        (in complete remission) or active HLH. Note that this diagnosis is distinct from
        post-transplant lymphoproliferative disorder/ EBV-associated lymphoproliferative disease
        (PTLD/LPD). [Patients must meet all of the following: a. Severe progressive illness,
        usually with fever, lymphadenopathy and splenomegaly that either began as primary EBV
        infection or was associated with markedly elevated antibody titers to EBV viral capsid
        antibody (≥ 1:5120) or early antigen (≥ 1:640), or markedly elevated EBV DNA in the blood;
        - AND - b. Infiltration of tissues (e.g., lymph nodes, liver, lungs, CNS, bone marrow, eye,
        skin) with lymphocytes; - AND - c. Elevated EBV DNA, RNA or proteins in affected tissues; -
        AND - d. The absence of HIV or post-transplant lymphoproliferative disorder]

        2C. Chronic granulomatous disease with indication for HCT [a. Oxidative burst &lt; 10% normal
        with dihydrorhodamine (DHR) assay - AND - b. Documented CGD mutation(s) in gp91phox,
        p47phox, p67phox, p22phox or p40phox - AND - c. Severe disease as evidenced by one or more
        of the following: history of one or more potentially life-threatening infections;
        inflammatory bowel disease; failure to thrive with height &lt;10% for age (unless parent(s)
        height &lt;10%); or autoimmune complication felt to be linked to CGD]

        2D. X-linked Hyper IgM Syndrome (HIGM1) [a. Decreased serum IgG (more than 2 standard
        deviations below normal for age) - AND - b. Mutation in CD40LG - OR - family history of
        maternally related males with HIGM1]

        2E. IPEX Syndrome [a. Absent FOXP3+ CD4+ T cells - OR - abnormal function of FOXP3+CD4+ T
        cells - AND - b. Disease-associated mutation in FoxP3 (bi-allelic in females) - OR - family
        history of maternally related males with clinical diagnosis of IPEX]

        2F. Severe Leukocyte Adhesion Deficiency, type I (LAD-I) [a. Decreased CD18 expression on
        neutrophils (&lt;5% normal for age) - AND - b. Mutation of ITGB2 - OR - absence of ITGB2 mRNA
        in leukocytes]

        3. Lansky or Karnofsky performance status ≥ 50%.

        4. The patient's donor must be willing and able to give bone marrow stem cells and be:

        a. An unaffected sibling donor who is a 6/6 match at HLA-A and -B (intermediate or higher
        resolution) and -DRB1 (at high resolution using DNA-based typing) OR b. An unaffected
        related donor (other than sibling) who is a 7/8 or 8/8 match for HLA-A, -B, -C (at
        intermediate or higher resolution) and -DRB1 (at high resolution using DNA-based typing) OR
        c. An unrelated donor who is a 7/8 or 8/8 match at HLA-A, -B, -C, and -DRB1 (at high
        resolution using DNA-based typing).

        5. Patient must have adequate organ function as measured by:

          1. Cardiac: Left ventricular ejection fraction (LVEF) &gt; 40%; or LV shortening fraction
             (LVSF) &gt; 26% by echocardiogram.

          2. Renal: Calculated or radioisotope Glomerular Filtration Rate (GFR) &gt; 50 mL/min/1.73m^2

          3. Hepatic: Adequate liver function: serum conjugated (direct) bilirubin &lt; 2x upper limit
             of normal for age as per local laboratory (with the exceptions of isolated
             hyperbilirubinemia due to Gilbert's syndrome, or hyperbilirubinemia as the result of
             liver inflammation in the setting of persistent, active HLH); alanine aminotransferase
             (ALT) and aspartate aminotransferase (AST) &lt; 10x upper limit of normal as per local
             laboratory (with the exception of elevated transaminase levels as the result of liver
             inflammation in the setting of persistent, active HLH).

          4. Pulmonary: Patient may not be on mechanical ventilation support or have progressive
             pulmonary infection at the time of transplant; Pulmonary Function Testing (PFT) with
             forced expiratory volume in one second (FEV1) &gt; 50% of normal and Diffusing capacity
             of the lung for carbon monoxide (DLCO) corrected for Hgb &gt; 50% of normal. Patients
             unable to undergo PFTs should have stable respiratory status with SaO2 &gt; 90% on a
             maximum of 2L/min supplemental oxygen.

             6. Signed informed consent.

             Exclusion Criteria:

               1. Hematopoietic stem cell transplant within 6 months of enrollment.

               2. Uncontrolled bacterial, viral or fungal infection (currently receiving
                  appropriate antimicrobials and experiencing progression or no clinical
                  improvement) at time of enrollment. We recognize that patients with CAEBV may
                  have ongoing EBV viremia at the time of initiating transplant therapy, but other
                  patients should have no uncontrolled bacterial, viral or fungal infections at the
                  time of enrollment (or prior to initiating the preparative regimen).

               3. Pregnant or breastfeeding.

               4. Seropositive for human immunodeficiency virus (HIV).

               5. Alemtuzumab within 2 weeks of enrollment.

               6. History of prior or current malignancy, especially malignancies with a likelihood
                  of relapse and progression, with the exception of (1) EBV-associated lymphomas
                  related to immune deficiency or lymphomas associated with X-linked LPD in a good
                  remission, as they are unlikely to relapse after treatment; (2) Resected basal
                  cell carcinoma or treated cervical carcinoma in situ. Cancer treated with
                  curative intent will not be allowed unless approved by the Protocol Officer or
                  one of the Protocol Chairs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614-3363</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105-2967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hosp-Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Click here for the Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <reference>
    <citation>Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825-8. Review.</citation>
    <PMID>7581076</PMID>
  </reference>
  <reference>
    <citation>Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56.</citation>
    <PMID>16338616</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2013</study_first_posted>
  <results_first_submitted>March 29, 2018</results_first_submitted>
  <results_first_submitted_qc>May 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2018</results_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophagocytic lymphohistiocytosis</keyword>
  <keyword>Chronic Active EBV</keyword>
  <keyword>Chronic Granulomatous Disease</keyword>
  <keyword>Hyperimmunoglobulin M Syndrome (Hyper IGM)</keyword>
  <keyword>Leukocyte Adhesion Deficiency</keyword>
  <keyword>IPEX</keyword>
  <keyword>Hematopoietic Stem Cell Transplant (HSCT)</keyword>
  <keyword>Non-Myeloablative Transplant (NST)</keyword>
  <keyword>Reduced-Intensity Conditioning (RIC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings will be published in a manuscript.</ipd_description>
    <ipd_time_frame>Within 6 months of official study closure at participating sites.</ipd_time_frame>
    <ipd_access_criteria>Available to the public.</ipd_access_criteria>
    <ipd_url>https://biolincc.nhlbi.nih.gov/home/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hemophagocytic Lymphohistiocytosis (HLH)</title>
          <description>Participants with Hemophagocytic Lymphohistiocytosis</description>
        </group>
        <group group_id="B2">
          <title>Other Primary Immune Deficiencies (PID)</title>
          <description>Participants with other primary immune deficiencies, including chronic active EBV disease, chronic granulomatous disease, hyper-immunoglobulin M syndrome, and immune dysregulation, polyendocrinopathy, enteropathy and X-linked (IPEX) syndrome</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0-9 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10-19 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>20-29 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Score (KPS)</title>
          <description>KPS describes patient-perceived global quality of life and functioning on a scale of 0-100.
100: No evidence of disease; 90: Normal activity. Minor signs or symptoms of disease; 80: Normal activity with effort. Some signs or symptoms of disease; 70: Cares for self. Unable to continue normal activity; 60: Needs occasional assistance, but cares for most personal needs; 50: Needs considerable assistance and medical care; 40: Disabled. Needs special care and assistance; 30: Severely disabled. Hospital admission indicated; 20: Very sick. Active supportive therapy needed; 10: Moribund; 0: Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>90-100</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>80</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>70</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>60</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>50</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Immune Deficiency Type</title>
          <population>Participants with Primary Immune Deficiencies</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Chronic Active Epstein-Barr Virus</title>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chronic Granulomatous Disease</title>
                  <measurement_list>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hyperimmunoglobulin M Syndrome</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IPEX</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Type</title>
          <description>HLA matching and relatedness of donor to recipient</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>HLA Matched Sibling</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 HLA Locus Mismatched Relative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HLA Matched Unrelated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 HLA Locus Mismatched Unrelated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Overall Survival (OS)</title>
        <description>Overall survival is defined as survival of death from any cause.</description>
        <time_frame>1 year and 18 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS)</title>
          <description>Overall survival is defined as survival of death from any cause.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="68.6" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 month OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="52.9" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Survival (OS) by Disease Type</title>
        <description>Overall survival is defined as survival of death from any cause.</description>
        <time_frame>1 year and 18 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hemophagocytic Lymphohistiocytosis (HLH)</title>
          </group>
          <group group_id="O2">
            <title>Other Primary Immune Deficiencies (PID)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS) by Disease Type</title>
          <description>Overall survival is defined as survival of death from any cause.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" lower_limit="68.4" upper_limit="90.6"/>
                    <measurement group_id="O2" value="75.0" lower_limit="47.4" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 month OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="51.8" upper_limit="79.7"/>
                    <measurement group_id="O2" value="62.5" lower_limit="32.7" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of HLH Participants With HLH Reactivation Post-Transplant</title>
        <description>Systemic HLH Reactivation: Post-transplant HLH reactivation is defined by clinical and lab evidence of pathologic inflammation (persistent fever, progressive cytopenias, rising ferritin and soluble IL2Rα, decreasing fibrinogen, hepatosplenomegaly, end-organ damage) not attributable to other causes.
Central nervous system (CNS) HLH Reactivation: Reactivation of CNS inflammation in patients with HLH may present with or without altered mental status and is defined by pleocytosis in Cerebrospinal fluid (CSF) or an MRI consistent with CNS inflammation not attributable to other causes.</description>
        <time_frame>1 year post-transplant</time_frame>
        <population>Participants with HLH</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of HLH Participants With HLH Reactivation Post-Transplant</title>
          <description>Systemic HLH Reactivation: Post-transplant HLH reactivation is defined by clinical and lab evidence of pathologic inflammation (persistent fever, progressive cytopenias, rising ferritin and soluble IL2Rα, decreasing fibrinogen, hepatosplenomegaly, end-organ damage) not attributable to other causes.
Central nervous system (CNS) HLH Reactivation: Reactivation of CNS inflammation in patients with HLH may present with or without altered mental status and is defined by pleocytosis in Cerebrospinal fluid (CSF) or an MRI consistent with CNS inflammation not attributable to other causes.</description>
          <population>Participants with HLH</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="5.2" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Neutrophil Engraftment</title>
        <description>Time to absolute neutrophil count (ANC) engraftment is defined as the first of three measurements on different days that the patient has an absolute neutrophil count of ≥ 500x10^6/liter following conditioning regimen induced nadir.</description>
        <time_frame>Day 42 post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Neutrophil Engraftment</title>
          <description>Time to absolute neutrophil count (ANC) engraftment is defined as the first of three measurements on different days that the patient has an absolute neutrophil count of ≥ 500x10^6/liter following conditioning regimen induced nadir.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Platelet Engraftment</title>
        <description>Platelet engraftment is defined as the first day of a minimum of three measurements on different days that the patient has achieved a platelet count &gt; 20,000 / microliter AND the patient is platelet transfusion independent for a minimum of seven days following conditioning regimen induced nadir.</description>
        <time_frame>Day 100 post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Platelet Engraftment</title>
          <description>Platelet engraftment is defined as the first day of a minimum of three measurements on different days that the patient has achieved a platelet count &gt; 20,000 / microliter AND the patient is platelet transfusion independent for a minimum of seven days following conditioning regimen induced nadir.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="73.3" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive With Sustained Engraftment</title>
        <description>Sustained engraftment is defined as the occurrence of whole blood donor chimerism &gt; 5% by Day 42 accompanied by the absence of any primary or secondary graft failure. Primary graft failure is defined as &lt; 5% donor chimerism by Day +42, second stem cell infusion, DLI (except in the case of donor CTLs given for infection control), or second HCT following original HCT. Secondary graft failure is defined as &lt; 5% donor chimerism following initial engraftment.</description>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive With Sustained Engraftment</title>
          <description>Sustained engraftment is defined as the occurrence of whole blood donor chimerism &gt; 5% by Day 42 accompanied by the absence of any primary or secondary graft failure. Primary graft failure is defined as &lt; 5% donor chimerism by Day +42, second stem cell infusion, DLI (except in the case of donor CTLs given for infection control), or second HCT following original HCT. Secondary graft failure is defined as &lt; 5% donor chimerism following initial engraftment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="25.1" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive With Sustained Engraftment by Disease Type</title>
        <description>Sustained engraftment is defined as the occurrence of whole blood donor chimerism &gt; 5% by Day 42 accompanied by the absence of any primary or secondary graft failure. Primary graft failure is defined as &lt; 5% donor chimerism by Day +42, second stem cell infusion, DLI (except in the case of donor CTLs given for infection control), or second HCT following original HCT. Secondary graft failure is defined as &lt; 5% donor chimerism following initial engraftment.</description>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hemophagocytic Lymphohistiocytosis (HLH)</title>
            <description>Participants with Hemophagocytic Lymphohistiocytosis</description>
          </group>
          <group group_id="O2">
            <title>Other Primary Immune Deficiencies (PID)</title>
            <description>Participants with other primary immune deficiencies, including chronic active EBV disease, chronic granulomatous disease, hyper-immunoglobulin M syndrome, and immune dysregulation, polyendocrinopathy, enteropathy and X-linked (IPEX) syndrome</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive With Sustained Engraftment by Disease Type</title>
          <description>Sustained engraftment is defined as the occurrence of whole blood donor chimerism &gt; 5% by Day 42 accompanied by the absence of any primary or secondary graft failure. Primary graft failure is defined as &lt; 5% donor chimerism by Day +42, second stem cell infusion, DLI (except in the case of donor CTLs given for infection control), or second HCT following original HCT. Secondary graft failure is defined as &lt; 5% donor chimerism following initial engraftment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" lower_limit="24.7" upper_limit="59.3"/>
                    <measurement group_id="O2" value="33.3" lower_limit="9.9" upper_limit="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Graft-Versus-Host Disease (GVHD)</title>
        <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Graft-Versus-Host Disease (GVHD)</title>
          <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0 or I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade II-IV and Grade III-IV Acute GVHD</title>
        <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
        <time_frame>Day 100 and 6 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade II-IV and Grade III-IV Acute GVHD</title>
          <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade II-IV Acute GVHD at Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="8.1" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade II-IV Acute GVHD at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="14.4" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III-IV Acute GVHD at Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="4.0" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III-IV Acute GVHD at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="8.1" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic GVHD</title>
        <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe.</description>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic GVHD</title>
          <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Chronic GVHD</title>
        <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification.</description>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Chronic GVHD</title>
          <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="14.6" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year post-transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
Hematopoietic Stem Cell Transplant: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Post transplant lymphoproliferative disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal, PhD</name_or_title>
      <organization>The Emmes Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

